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A b s t r A c t
We present a novel, rare but recurrent, variant three-way translocation of t(8;21), 
t(8;16;21)(q22;q24;q22), resulting in RUNX1-RUNX1T1 fusion gene in a patient with 
acute myeloid leukemia expressing both myeloid and lymphoid markers. Our patient 
was considered as a high risk patient based on his single blast population with im-
munophenotypic evidence of simultaneous myeloid and B-lymphoid differentiation, 
the unknown implications of t(8;16;21) and the presence of minimal residual disease 
shortly after the last chemotherapy cycle. However, he had an excellent outcome after 
allogeneic stem cell transplantation and he is well and fully functional 4 years post 
diagnosis. This case could be advisable for prognostic and therapeutic purposes.
I N t r O D U c t I O N
Translocation t(8;21) found in ~5% of acute myeloid leukemia (AML) cases oc-
curs predominantly in young patients with AML-M2 and is generally associated with a 
favorable outcome. Complex cytogenetic variants of this translocation, most of which 
are three-way translocations, involving regions 8q22, 21q22 and a third chromosome, 
are observed in approximately 3% of all t(8;21) cases in AML. However, the clinical 
and pathological features of such cases are less characterized compared to the standard 
translocation and their clinical significance remains controversial.1-4 According to the 
World Health Organization (WHO) 2008, AML cases with t(8;21) may express B-cell 
markers (CD19 or to a lesser extent, CD7).5,6 These cases were previously diagnosed 
as biphenotypic acute leukemia according to the European Group of Immunological 
Markers for Leukemias (EGIL) scoring system when a score over 2 points was reached 
for the myeloid as well as 1 for the lymphoid lineage and were associated with a poor 
outcome.7-9
Herewith, we present a case of AML expressing both myeloid and B-lymphoid 
antigens with a novel variant translocation t(8;16;21)(q22;q24;q22), resulting in 
RUNX1-RUNX1T1 fusion gene which could be advisable for prognostic and thera-
peutic purposes.
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AbbreviAtions:
AML = acute myeloid leukemia
BCR-ABL = breakpoint cluster region 
- Abelson murine leukemia viral 
oncogene homolog 1 (fusion gene)
CBFB = core binding factor subunit 
beta 
EGIL = European Group of 
Immunological Markers for Leukemias 
FISH = fluorescence in situ hybridization
FLT3 = Fms-like tyrosine kinase 3 
GVHD = graft-versus-host disease 
MLL= mixed-lineage leukemia 
MRD = minimal residual disease 
NPM1 = nucleophosmin 1
PCR = polymerase chain reaction
WHO = World Health Organization
Conflict of Interest: none declared
NOVEL VARIANT TRANSLOCATION IN ACuTE MyELOID LEuKEMIA
175
c A s E  r E P O r t
On January 24, 2011, a 36-year old male was admitted 
to the hospital with weakness, fatigue and cytopenia. A full 
blood count showed a white blood cell count of 17,900/mm3, 
hematocrit of 16.9%, platelet count of 16,000/mm3, and mean 
corpuscular volume of 106 fL. Peripheral blood smear revealed 
35% blasts and mild dysplastic features. Bone marrow aspirate 
showed 43% blasts, positive for myeloperoxidase by cytochem-
istry. Flow cytometric analysis disclosed a single blast popula-
tion with evidence of simultaneous myeloid and B- lymphoid 
differentiation (CD34+, CD13+, CD33+, CD19+, CD38+, 
CD117+, weak TdT and HLA-DR expression). Cytogenetic 
analysis of bone marrow cells showed 2 abnormal clones with 
karyotypic evolution. The first clone was characterized by 
a three-way translocation between chromosomal regions 
8q22, 16q24 and 21q22 (Fig. 1), while the evolutionary clone 
showed additionally loss of chromosome y. The karyotype 
was described as: 46,Xy,t(8;16;21)(q22;q24;q22)[16]/45,X,-
y,t(8;16;21)(q22;q24;q22)[4]. Interphase and metaphase fluo-
rescence in situ hybridization (FISH) analysis using Vysis LSI 
RUNX1/RUNX1T1 Dual Color Dual Fusion Probes (Abbott 
Laboratories, Abbott Park, Illinois, uSA), showed that 87% 
of cells had 2 fusion signals, one on the derivative chromo-
some 8 and the other on the derivative chromosome 21 (Fig. 
2). Metaphase FISH, using the core binding factor subunit 
beta (CBFB) breaking apart probe showed that the CBFB 
gene was intact on the der(16), indicating that the breakpoint 
was distal to 16q22. Molecular diagnosis by polymerase chain 
reaction (PCR) for RUNX1-RUNX1T1 fusion gene was not 
performed at the time of diagnosis or during the follow up of 
the patient. The diagnostic bone marrow sample was negative 
for “breakpoint cluster region” - Abelson murine leukemia vi-
ral oncogene homolog 1 (BCR-ABL) fusion gene and negative 
for Fms-like tyrosine kinase 3 (FLT3), nucleophosmin (NPM1) 
and mixed-lineage leukemia (MLL) mutations by PCR. 
The patient was commenced on antileukemic induction 
chemotherapy [idarubicin+cytarabine (3+10, 12 mg/M2 D1-
D3 +100 mg/M2 bid D1-D10) and dexamethasone 24 mg iv 
D1-D5] and achieved complete remission 28 days later. Four 
additional courses of consolidation multiagent chemotherapy 
were administered until June 11th of the same year in order to 
ensure continuing and deep complete remission. Following a 
treatment gap of several weeks, in September 2011, he was 
reevaluated and found to be in morphological remission but 
a small number of biphenotypic blasts (≤1%) was detected by 
flow cytometry. The patient’s leukemic characteristics and his 
disease evolution and behavior classified him as a high risk-
acute leukemia case in complete remission 1 (CR1), minimal 
residual disease (MRD)-positive and therefore eligible for 
allogeneic stem cell transplantation. He received an allogeneic 
graft from an unrelated 43-year-old male donor, who was 
histocompatible in 9/10 antigens. The patient’s Karnofsky 
performance status at transplant was 100%. Conditioning 
therapy consisted of busulfan/cyclophosphamide - alem-
tuzumab (BuCy-Campath) while graft-versus-host disease 
(GVHD) prophylaxis included cyclosporine and alemtuzumab 
monoclonal antibody. He received a total amount of 4.2x106/kg 
CD34(+) cells from his donor and engraftment was successful 
for the white blood cell count on day 11 and for platelets on day 
FIgUrE 1. G- banded bone marrow karyotype showing 
46,Xy,t(8;16;21)(q22;q24;q22).
FIgUrE 2. FISH using LSI RUNX1-RUNX1T1 dual-color 
dual fusion probe showing one red signal corresponding to 
RUNX1T1 gene on the normal chromosome 8, one green signal 
corresponding to RUNX1 gene on the normal chromosome 21 
and two yellow fusion signals (RUNX1-RUNX1T1) located on 
der(8) and der(21). FISH = fluorescence in situ hybridization.
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13. On day 176 post transplantation a new bone marrow biopsy, 
flow cytometry and cytogenetic analysis, confirmed that our 
patient was in continuous morphological, immunophenotypic 
and cytogenetic remission. The patient remains well and in full 
activities until now, 4 years post diagnosis.
D I s c U s s I O N
Variant forms of the classic translocation t(8;21) are 
uncommon in acute myeloid leukemia (AML) patients and 
their prognostic significance is still controversial. This could be 
partly attributed to the third implicated chromosome and its 
breakpoints involved in the translocation. These breakpoints 
in a variant three-way translocation may disturb the normal 
function of hematopoietic cells and subsequently be crucial 
for the clinical course of the disease. Band 16q24, involved 
in our case, is a very important chromosomal region not only 
because it carries tumor suppressor genes but because it is 
also implicated in the translocation t(16;21)(q24;q22), which 
is a recurrent translocation in AML with poor prognosis.10 A 
systematic review of the literature revealed that t(8;16;21) 
has been reported only once in a patient with AML-M2, con-
firming that this is a rare but recurrent aberration in AML.11 
unfortunately, the clinical course and outcome of that patient 
is not available and the prognostic significance of t(8;16;21)
(q22;q24;q22) is currently unknown.
Our patient was diagnosed with AML carrying a novel 
variant translocation of t(8;21), according to WHO 2008 clas-
sification. He was considered as a high risk patient on the basis 
of his single blast population with immunophenotypic evidence 
of simultaneous myeloid and B-lymphoid differentiation, the 
unknown implications of t(8;16;21) and the presence of mini-
mal residual disease shortly after the last chemotherapy cycle. 
On those grounds and due to the availability of a matched 
unrelated donor it was decided to receive an allogeneic graft 
whilst in first complete remission. So far, 4 years post diagnosis 
he remains in good condition and carries a normal life.
In conclusion, t(8;16;21)(q22;q24;q22) is a novel, rare but 
recurrent variant translocation of t(8;21), resulting in RUNX1-
RUNX1T1 fusion gene . In this case, t(8;16;21) was found 
in an AML patient with a single blast population showing 
simultaneous expression of myeloid and B- lymphoid mark-
ers negative for FLT3, NPM1 and MLL mutations. Patients 
with this translocation may have a favorable outcome after 
allogeneic stem cell transplantation.
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